News - NLSDays - NLSDays

Latest news in cooperation with Nordic Life Science

CNS diseases – Is the last complex medical enigma about to be solved?

24 April 2024 | 1:02 pm

Novel AI model detects 90% of lymphatic cancer cases

24 April 2024 | 8:56 am

Researchers at Chalmers University of Technology in Sweden have carried out one of the largest studies to date using AI (artificial intelligence)-assisted image analysis of lymphoma. “An AI-based computer system for interpreting medical images also contributes to increased equality in healthcare by giving patients access to the same expertise and being able to have their […]

Spago Nanomedical reports favorable data

24 April 2024 | 8:33 am

The company has announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 demonstrates superior anti-tumor effect compared to standard cancer drugs with a low and acceptable level of radiotoxicity observed, states the company. “Triple-negative breast cancer is a very aggressive disease with poor prognosis. The […]

AstraZeneca’s Voydeya approved in the EU as add-on treatment

24 April 2024 | 4:35 am

Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of […]

The winners of HackHERHealth

23 April 2024 | 1:27 pm

In the beginning of March, Sahlgrenska Science Park, GoCo Health Innovation City, AstraZeneca, and other members of Health Innovation West invited participants, students, researchers, tech enthusiasts, life science experts, entrepreneurs, and others to a femtech innovation hackathon, a hackaton focused on reducing the gender health gap and advancing women’s health. Initiators of the hackaton were […]

Mia Phillipson – Pioneering immunotherapies

23 April 2024 | 4:52 am

Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur. “Most of all, I am a scientist. Yes, absolutely. This is my main occupation and the one in which I have the most expertise,” says Mia Phillipson, who […]

Nykode initiates Phase 2 trial in second line HPV16-positive cervical cancer

22 April 2024 | 8:19 am

The company has announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq) in patients with HPV16positive, PD-L1-positive, recurrent, or metastatic cervical cancer. “Initiating the VB10.16 trial for HPV16-positive cervical cancer […]

BioArctic and Eisai sign research evaluation agreement

22 April 2024 | 8:08 am

The two companies have entered into an agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease. “I […]

Building and bridging the most innovative life science cluster in the EU

17 April 2024 | 1:06 pm

Boston’s Kendall Square, close to Massachusetts Institute of Technology (MIT), is known as “The most innovative square mile on the planet” and, apart from our preference for the metric system, there just might be something we could learn from the Americans. One of the recommendations is that public and private stakeholders, inspired by the success […]

Ultimovacs implements operational adjustments, including reducing its workforce

17 April 2024 | 8:36 am

Ultimovacs has announced a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several cancer indications and immunotherapy combinations, and we are prepared for both challenges and accomplishments along the way. We anticipate […]

Latest news in cooperation with Nordic Life Science

CNS diseases – Is the last complex medical enigma about to be solved?

Novel AI model detects 90% of lymphatic cancer cases

Spago Nanomedical reports favorable data

AstraZeneca’s Voydeya approved in the EU as add-on treatment

The winners of HackHERHealth

Mia Phillipson – Pioneering immunotherapies

Nykode initiates Phase 2 trial in second line HPV16-positive cervical cancer

BioArctic and Eisai sign research evaluation agreement

Building and bridging the most innovative life science cluster in the EU

Ultimovacs implements operational adjustments, including reducing its workforce

Join the conference!

Join the conference!

© 2024 SwedenBIO. All Rights Reserved
Legal Notices

Latest news in cooperation with Nordic Life Science

Join the conference!

© 2024 SwedenBIO. All Rights ReservedLegal Notices

© 2024 SwedenBIO. All Rights Reserved
Legal Notices